Treatment of acute leukemia and malignant lymphoma with (2″R)-4′-O-tetrahydropyranyladriamycin


Eighty-four previously treated adult patients with acute leukemia and malignant lymphoma were treated with (2″R)-4′-O-tetrahydropyranyladriamycin (THP). THP (10–55 mg/m2) was administered by i.v. bolus injection daily for acute leukemia, and according to three different schedules for malignant lymphoma: daily, weekly or once every 3–4 weeks. Complete and partial remission (CR and PR) were achieved by 1 (5%) and 3 of 19 patients with acute myelogenous leukemia and by 2 (13%) and 3 of 15 patients with acute lymphoblastic leukemia, respectively. All CRs were in the groups receiving 25 mg/m2 THP daily. CR and PR were achieved by 6 (14%) and 8 of 42 patients with non-Hodgkin lymphoma (NHL) and by 4 (50%) and 2 of 8 patients with Hodgkin's disease (HD), respectively. No particular sensitivity was found among the subtypes of NHL and HD. Response (CR+PR) was noted in 10 (40%) of 25 patients treated every 3–4 weeks, in 1 (17%) of 6 treated weekly, and in 9 (47%) of 19 treated daily. The major side effects were myelosuppression and gastrointestinal toxicities. Alopecia was observed in only 10 (12%) patients. ECG abnormalities were observed in 7 (10%) patients, all of whom had previously been treated with other anthracyclines. No severe cardiotoxicity was observed.

DOI: 10.1007/BF00570491

6 Figures and Tables


Citations per Year

228 Citations

Semantic Scholar estimates that this publication has 228 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Ohno1987TreatmentOA, title={Treatment of acute leukemia and malignant lymphoma with (2″R)-4′-O-tetrahydropyranyladriamycin}, author={Ryuzo Ohno and Kiyoji Kimura and Ichita Amaki and Masami Hirano and Akira Hoshino and Yasushi Ikeda and Ikuro Kimura and Masahide Kobayashi and Kiyoshi Konno and Hisashi Majima and Toru Masaoka and Harumitsu Mizuno and Makoto Ogawa and Masao Oguro and Tatuo Saito and Masanori Shimoyama and Shigeru Shirakawa and Yuzuru Sugawara and Fumimaro Takaku and Hideo Yamada and Kazumasa Yamada and Kaoru Yamagata and Yutaka Yoshida and Satoshi Yoshikawa and Akira Wakui}, journal={Cancer Chemotherapy and Pharmacology}, year={1987}, volume={20}, pages={230-234} }